Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RMD vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RMD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)
RMD Overall Winner
6-Pillar Tally: RMD 3 – 3 DCTH
Matrix Metrics: RMD 8 – 2 DCTH
As of Nov 16, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). RMD carries a Unified Composite Score of 59.0/100 (HOLD) at $239.34 (19.8x Forward P/E, 34.0% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).
- Growth vs. Quality Trade-Off: RMD earns the overall head-to-head edge with a stronger Unified Composite Score (59.0/100 HOLD vs. DCTH 35.9/100 SELL) and 0.41β · 43% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RMD vs DCTH
RMD
Head-to-Head Winner
ResMed Inc.
$239.34
-0.08% 1D
Market Cap
$33.6B
TTM Revenue
$5.73B
Forward P/E
19.8x
Beta / 30D Vol
0.41β · 43% Vol
Unified Composite Score
59.0
HOLD
Tech 62.0
Fund 59.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
DCTH
Delcath Systems Inc
$19.68
-4.23% 1D
Market Cap
$743.8M
TTM Revenue
$110M
Forward P/E
N/M
Beta / 30D Vol
1.63β · 131% Vol
Unified Composite Score
35.9
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (RMD 3 – 3 DCTH)
1. Valuation Multiples
RMD
Forward P/E
19.8x
N/M
Trailing P/E
21.8x
133.6x
PEG Ratio
1.28x
1.60x
EV / Revenue
5.8x
6.3x
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+5.9%
+70.7%
Earnings Growth (YoY)
+23.2%
+750.0%
TTM Revenue (USD)
$5.73B
$110M
Market Cap
$33.6B
$743.8M
3. Profitability & Quality
RMD
Gross Margin
61.8%
87.6%
Operating Margin
34.0%
5.2%
Net Profit Margin
27.8%
6.0%
Return on Equity (ROE)
26.4%
5.4%
4. Balance Sheet & Cash Flow
RMD
Cash Generation (TTM)
$1.59B
$20M
Cash Flow Margin
27.7%
18.3%
Net Cash / Leverage
$400M Net Cash
$53M Net Cash
Dividend Yield
1.03%
None (0.00%)
5. Options & Positioning
DCTH
Options Structure Phase
CONSOLIDATION
BREAKOUT
Current IV / %ile
28.2% (22nd %ile)
109.3% (43rd %ile)
Put/Call OI Skew
2.00x (Put-Skewed)
0.11x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Markup
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
27.8% of Rev ($1.59B)
82.4% of Rev ($91M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Instruments & Supplies Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RMD (8) vs DCTH (2)| Institutional Metric | RMD | DCTH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $33.6B | $743.8M | RMD | |
| Trailing P/E Ratio | 21.8x | 133.6x | RMD | |
| Forward P/E Ratio | 19.8x | N/M | RMD | |
| Revenue Growth (YoY) | +5.9% | +70.7% | DCTH | |
| Operating Margin (TTM) | 34.0% | 5.2% | RMD | |
| Net Profit Margin | 27.8% | 6.0% | RMD | |
| Return on Equity (ROE) | 26.4% | 5.4% | RMD | |
| 52-Week Range Position | 61% ($180–$278) | 80% ($8–$23) | DCTH | |
| Beta / 30D Volatility | 0.41β · 43% Vol | 1.63β · 131% Vol | RMD | |
| Unified Institutional Score | 59.0 / 100 (HOLD) | 35.9 / 100 (SELL) | RMD | |
| Trailing 12M Revenue (USD) | $5.73B | $110M | Scale | |
| Gross Profit Margin (TTM) | 61.8% | 87.6% | Quality | |
| PEG Ratio & EV / Revenue | 1.28x PEG · 5.8x EV/Rev | 1.60x PEG · 6.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $1.59B ($400M Net Cash) | $20M ($53M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DCTH +39.61 pp
3M Horizon
DCTH +7.93 pp
6M Horizon
DCTH +60.22 pp
1Y Horizon
DCTH +133.63 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RMD Revenue | DCTH Revenue | RMD Op. Margin | DCTH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $2.61B | N/A | 22.2% | N/A | RMD |
| FY2020 | $2.96B | N/A | 27.4% | N/A | RMD |
| FY2021 | $3.20B | $0M | 28.3% | -690.0% | RMD |
| FY2022 | $3.58B | $0M | 28.0% | -1245.1% | RMD |
| FY2023 | $4.22B | $0M | 26.8% | -1849.0% | RMD |
| FY2024 | $4.69B | $40M | 28.2% | -33.4% | RMD |
| FY2025 | $5.15B | $90M | 32.7% | 0.8% | RMD |
| FY2026 | $5.65B | N/A | 33.4% | N/A | RMD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RMD
CONSOLIDATION
Current IV
28.2%
IV Percentile
22nd %ile
Put/Call OI Skew
2.00x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DCTH
BREAKOUT
Current IV
109.3%
IV Percentile
43rd %ile
Put/Call OI Skew
0.11x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RMD Moat Profile
High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
27.8% of Rev ($1.59B)
90D Engineering Disclosures
0 Published
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
Investor FAQ RMD vs DCTH Key Questions & Quantitative Answers
As of Nov 16, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). RMD carries a Unified Composite Score of 59.0/100 (HOLD) at $239.34 (19.8x Forward P/E, 34.0% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Growth vs. Quality Trade-Off: RMD earns the overall head-to-head edge with a stronger Unified Composite Score (59.0/100 HOLD vs. DCTH 35.9/100 SELL) and 0.41β · 43% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
DCTH leads the Growth & Scale pillar: RMD posts +5.9% YoY revenue growth and +23.2% YoY earnings growth on $5.73B TTM revenue (61.8% gross margin, 34.0% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), RMD cumulative revenue shifted +116.5% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, RMD deploys 27.8% of Rev ($1.59B) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
RMD screens cheaper on headline valuation multiples. RMD trades at 19.8x Forward P/E, 21.8x Trailing P/E, 1.28x PEG, and 5.8x EV/Revenue (27.7% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RMD (26.4% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, RMD carries 28.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.00x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.41β · 43% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DCTH vs RMD · Reverse Pair
RMD vs STE
· Sector Peer
RMD vs COO
· Sector Peer
RMD vs MTD
· Sector Peer
DCTH vs CRMD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma